Market Overview

Celsion Expects To Begin Enrollment Of Phase I Portion Of The OVATION II Study Of GEN-1 During First Half Of 2018 In Up to 90 Patients, Says Phase I/II Study Will Be Powered To Show A 33% Improvement In The Primary Endpoint, Progression Free Survival

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: FDA

 

Related Articles (CLSN)

Markets Might React To Tough Talk On Tariffs, Potential European Instability

Monster Beverage Is A 'Compelling Growth Story,' Deutsche Bank Says In Upgrade